Nov 27, 2024 · Gleevec is a targeted therapy cancer treatment used to treat specific types of leukemia (blood cancer), bone marrow disorders, skin cancers and certain tumors of the stomach and …

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2]

The recommended dose of Gleevec is 400 mg/day for adult patients with ASM without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with Gleevec 400 mg/day …

COMMON BRAND NAME (S): Gleevec What should I tell my care team before I take this medication? They need to know if you have any of these conditions: Bleeding disorder Infection, especially a viral …

Feb 13, 2025 · Find patient medical information for Imatinib (Gleevec, Imkeldi) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

What is this medication? IMATINIB (i MAT in ib) treats some types of cancer. It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer …

Apr 11, 2018 · NCI-supported research led to a series of discoveries that resulted in the development of imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with a type of …

Jun 9, 2019 · Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

An open-label, multicenter, randomized trial (Gleevec versus nilotinib) was conducted to determine the efficacy of Gleevec versus nilotinib in adult patients with cytogenetically confirmed, newly diagnosed …

Medscape - Multiple indication dosing for Gleevec, Imkeldi (imatinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...